Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 13, 2019 | June 14, 2019 |
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director | June 12, 2026 | June 17, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | February 28, 2022 | March 02, 2022 |
| Verastem, Inc.VSTM · Entity 5242 | Director · President of Development | January 06, 2026 | January 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INFINITY PHARMACEUTICALS, INC.
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2029-06-12 | Direct | 30,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
KYNTRA BIO, INC.
Report date June 12, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11 | Direct | 7,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.
Karyopharm Therapeutics Inc.
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 713,757 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Grant · Acquired 21,000 · Balance 719,983 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Row 2 · 2022-02-28 · Sale · Disposed 6,226 · Balance 713,757 F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 898,131 |
Reported balance
After 2022-02-28 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-02-28 · Sale · Disposed 6,226 · Balance 898,131 F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-02-27 | Direct | 27,000 |
Reported balance
After 2022-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-28 · Grant · Acquired 27,000 · Balance 27,000 F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
F5: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Verastem, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2036-01-06 | Direct | 200,000 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 33.33% of the shares on the first anniversary of January 6, 2026 (the "Grant Date"), and an additional 8.33% will vest at the end of each successive three-month period following the first anniversary of the Grant Date until the third anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest) provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adicet Bio, Inc.
Report date August 21, 2024 · Filed August 23, 2024
Section 16 reporting ended · disclosed 2024-08-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-11-16 | Direct | 0 |
Reported balance
After 2024-08-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-21 · Disposition to issuer · Disposed 37,000 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2031-11-16 | Direct | 37,000 |
Reported balance
After 2024-08-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-21 · Grant · Acquired 37,000 · Balance 37,000 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2024-08-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-21 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2032-06-01 | Direct | 18,500 |
Reported balance
After 2024-08-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-21 · Grant · Acquired 18,500 · Balance 18,500 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2024-08-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-21 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.20 · Expires 2033-05-31 | Direct | 26,400 |
Reported balance
After 2024-08-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-21 · Grant · Acquired 26,400 · Balance 26,400 F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: The shares subject to this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
F3: The shares subject to this option are fully vested and exercisable as of the date hereof.
Kezar Life Sciences, Inc.
Report date May 11, 2026 · Filed May 11, 2026
Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Other · Disposed 6,369 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.10 · Expires 2028-04-15 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-11 · Disposition to issuer · Disposed 389 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-11 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2034-06-19 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2029-06-24 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Disposition to issuer · Disposed 889 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2031-06-27 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")
F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2018 Filed Jan 9, 2018 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-002913 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-066638 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,424 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $9.16 | $91,553.00 |
DisclosureSEC source: 0001209191-17-066638 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.0501 to $9.3500, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-17-066638 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-064687 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 29,394 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $10.39 | $103,903.00 |
DisclosureSEC source: 0001209191-17-064687 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.48, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-17-064687 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · balance_after: Reflects the contribution of 60,000 shares previously owned directly by the spouse of the reporting person to the Sharon Shacham 2016 Qualified Annuity Interest Trust ("Spouse's GRAT") on September 9, 2016 and the transfer of 12,691 shares from the Spouse's GRAT to the spouse of the reporting person on November 6, 2017. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:21 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001104659-17-039559 · a4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 08:27 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000899243-17-009627 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-04-05 F1 · derivative.exercise_date: The option vests as to 1/8th of the shares on June 30, 2017 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:30 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005322 · doc4.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:30 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005322 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.